RXi Pharmaceuticals is a discovery-stage biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi) for the treatment of human diseases. 

RXi intends to utilize a broad platform of RNAi-based technologies across multiple therapeutic areas with an initial focus on the treatment of neurological diseases, metabolic diseases and cancer.  RNAi is a naturally occurring mechanism for the regulation of gene expression that has the potential to be harnessed to selectively inhibit the activity of any human gene.  It is believed that this inhibition may potentially treat human diseases by “turning-off” genes that lead to disease.

RXi was founded by world-leading researchers in the field of RNAi, including Dr. Craig Mello, recipient of the 2006 Nobel Prize for Medicine for his co-discovery of RNAi, and Blais University Chair of Molecular Medicine at the University of Massachusetts Medical School, or UMMS.  The Company began operations in January 2007 for the purpose of accelerating the discovery of RNAi therapeutics.